Europe · Financial press · Financial Times
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector
Detailed summary
Summit’s Ivonescimab was seen as a test case for whether the country’s medicine could pass scrutiny in the US
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.ft.com)
